statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced data presented during the 56th European Society for Paediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting which...

Mirum Pharmaceuticals LIVMARLI Data Showcased at ESPGHAN Annual Meeting

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on May 10, 2024, the Compensation Committee of Mirums Board of Directors granted inducement awards consisting of non-qualified stock...

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Latest Ratings for MIRM
 DateFirmActionFromTo Mar 2022Raymond JamesMaintainsStrong Buy Jan 2022SVB LeerinkMaintainsOutperform Jan 2022Raymond JamesMaintainsStrong Buy
 View More Analyst Ratings...

Analyst Ratings For Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for first quarter 2024 and provided a business update. In the first quarter, we made great progress across a number of our...

Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and...

Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that data from the Phase 3 MARCH-PFIC study evaluating LIVMARLI (maralixibat) oral solution in patients with PFIC was published in The...

Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter 2024 financial results on May 8, 2024. Mirum will also host a conference call to discuss the first quarter...

Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on April 10, 2024, the Compensation Committee of Mirums Board of Directors granted inducement awards consisting of non-qualified stock...

HC Wainwright reiterated their buy rating on shares of Mirum Pharmaceuticals (NASDAQ:MIRM - Free Report) in a research report report published on Tuesday morning, Benzinga reports. They currently...

HC Wainwright Reaffirms "Buy" Rating for Mirum Pharmaceuticals (NASDAQ:MIRM)

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Mirum Pharmaceuticals participates in a conference call with JPMorgan

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Watchers	1,420
52-Wk Low	$23.14
52-Wk High	$35.56

Volume	779,083.00
52-Wk High	$35.56
52-Wk Low	$23.14

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.44	--	--	N/A
Q1'24	-$0.42	-$0.54	-28.49%	MISSED
Q4'23	-$0.24	-$0.63	-162.39%	MISSED
Q3'23	-$0.63	-$0.57	9.27%	BEAT
Q2'23	-$0.80	-$1.94	-143.89%	MISSED

MIRM Mirum Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals